ViewRay® Announces First International MRIdian® Installation at Seoul National University Hospital

Clinical Team Prepares for Adaptive Therapy and Other Advanced MRI-Guided Treatments

Sep 15, 2015, 08:31 ET from ViewRay, Inc.

CLEVELAND, Sept. 15, 2015 /PRNewswire/ -- ViewRay, Inc. (OTCQB:VRAY) announced today the first international installation of its MRIdian System, the world's first and only MRI-guided radiation therapy system that images and treats patients simultaneously, at Seoul National University Hospital, a leading healthcare facility in Korea.

"We pride ourselves on offering the most advanced, state-of-the-art treatment options to our patients; therefore, MRI-guided radiation therapy was a must-have," said Hong-Gyun Wu, M.D., Ph.D., Professor and Department Chairman of Seoul National University Hospital. "We are proud to be the first MRI-guided therapy center in Asia and one of the first in the world to use this breakthrough technology. The MRIdian system allows us to see the tumor and surrounding soft tissues both before and during treatment, so we can adapt to changes in the patient's anatomy." 

The SNUH team expects to begin treating patients in the next few weeks and intends to develop various treatment protocols and publish their research. Along with treatments of the lung, liver and breast, an area of particular interest to the hospital is the use of MRIdian for spine radiosurgery due to its ability to view the spine, spinal cord and adjacent tissue during treatment.

"The installation at SNUH is our first overseas installation and the beginning of our international expansion as MR-guided radiation therapy is embraced as an indispensable tool in the treatment of cancer," said Chris A. Raanes, President and Chief Executive Officer of ViewRay. "We are pleased to be working with such a world-class research institution. This marks the start of bringing the multiple benefits of MRIdian to patients around the world." 

The Cancer Hospital at Seoul National University Hospital opened in March 2011 and is dedicated to providing the best medical service to cancer patients. It is made up of 15 cancer specialty centers and nine multidisciplinary cancer treatment centers. The center offers state-of-the-art medical systems, world-class R&D capabilities and doctors skilled in the treatment of cancer.

About ViewRay

ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

Forward Looking Statements:

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to treatment of patients and research plans at SNUH, future international sales of MRIdian and the use of MR-guided radiation therapy in the treatment of cancer. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize MRIdian, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at

SOURCE ViewRay, Inc.